M. Inomata, K. Azechi, N. Takata, K. Hayashi, K. Tokui, C. Taka, S. Okazawa, K. Kambara, S. Imanishi, T. Miwa, Ryuji Hayashi, Shoko Matsui, K. Tobe
{"title":"Impact of Immune Checkpoint Inhibitor on the Survival in Elderly Patients with Non-Small Cell Lung Cancer","authors":"M. Inomata, K. Azechi, N. Takata, K. Hayashi, K. Tokui, C. Taka, S. Okazawa, K. Kambara, S. Imanishi, T. Miwa, Ryuji Hayashi, Shoko Matsui, K. Tobe","doi":"10.31487/j.cor.2020.12.04","DOIUrl":null,"url":null,"abstract":"Purpose: We analysed the relationship between a history of immune checkpoint inhibitor (ICI) and overall\nsurvival in elderly patients with non-small cell lung cancer (NSCLC).\nMethods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70-year-old\nwho had received systemic anticancer therapy between 2015 and 2019.\nResults: The analysis included the data of a total of 63 patients. Multivariate analysis revealed a significant\nassociation between a history of treatment with ICI and the overall survival. A significant interaction was\nalso observed between a history of treatment with an ICI and the tumor histology.\nConclusion: A significant association between history of ICI therapy and the overall survival was detected\nin elderly NSCLC patients aged ≥70-year-old in a clinical practice setting. Our results also suggested that\nthe impact of ICI therapy on the survival differed depending on the tumor histology.\n","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"66 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Oncology and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/j.cor.2020.12.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We analysed the relationship between a history of immune checkpoint inhibitor (ICI) and overall
survival in elderly patients with non-small cell lung cancer (NSCLC).
Methods: We conducted a retrospective analysis of the data of patients with NSCLC aged ≥70-year-old
who had received systemic anticancer therapy between 2015 and 2019.
Results: The analysis included the data of a total of 63 patients. Multivariate analysis revealed a significant
association between a history of treatment with ICI and the overall survival. A significant interaction was
also observed between a history of treatment with an ICI and the tumor histology.
Conclusion: A significant association between history of ICI therapy and the overall survival was detected
in elderly NSCLC patients aged ≥70-year-old in a clinical practice setting. Our results also suggested that
the impact of ICI therapy on the survival differed depending on the tumor histology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
